Lynparza approved in China as first-line maintenance treatment with Bevacizumab for HRD- positive advanced ovarian cancer

One in two women with advanced ovarian cancer has an HRD-positive tumor

Lynparza with Bevacizumab demonstrates survival in certain patients with first-line advanced ovarian cancer

The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients

OvaCis rapid test to detect ovarian cancer gets CE mark

Revolutionary ovarian cancer rapid test available Q4 2022

Pebble engages MD Anderson to evaluate multi-cannabinoid formulations in ovarian cancer

Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care

U.S. FDA approves Cytalux injection for identifying ovarian cancer during surgery

It is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively, enabling the detection of more cancer for removal

Gilead to acquire Tubulis for up to $5 billion to strengthen its oncology portfolio

The acquisition complements Gilead’s existing oncology expertise and development infrastructure

Citius Oncology reports promising early trial results for therapy for gynecologic cancers

The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR

GSK India crosses Rs. 1,000 crore mark, key portfolios drive 8.1% topline growth

Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum

Vivere Oncotherapies secures more than $10M to tackle hard-to-treat ‘cold’ tumors

Zydus signs exclusive agreement with Myriad Genetics of US to launch cancer-risk assessment diagnostic tests in India